NYSE American · RGNT
Regentis Biomaterials financials
$1.85−2.12%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $0.00 |
| Gross profit | $0.00 |
| Gross margin | — |
| Operating income | -$7.0M |
| Net income | -$13.6M |
| Net margin | — |
| Diluted EPS | $-24.08 |
| EBITDA | -$7.0M |
| Operating cash flow | -$1.4M |
| Free cash flow | -$1.4M |
| Diluted shares | 0.6M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $7.4M |
| Short-term investments | $0.00 |
| Total debt | $1.2M |
| Total assets | $7.6M |
| Total liabilities | $2.9M |
| Shareholders' equity | $4.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology